Characterizing the Epothilone Binding Site on β-Tubulin by Photoaffinity Labeling: Identification of β-Tubulin Peptides TARGSQQY and TSRGSQQY as Targets of an Epothilone Photoprobe for Polymerized Tubulin
Abstract:Photoaffinity labeling with an epothilone A photoprobe led to the identification of the β-tubulin peptides TARGSQQY and TSRGSQQY as targets of the photoprobe for polymerized tubulin. These peptides represent residues 274–281 in different β-tubulin isotypes. Placing the carbene producing 21-diazo/triazolo moiety of the photoprobe in the vicinity of the TARGSQQY peptide in a homology model of TBB3 predicted a binding pose and conformation of the photoprobe that are very similar to the ones reported for 1) the hi… Show more
“…The final major category of tubulin inhibitors is colchicine binding site agents. Colchicine (17), from the meadow saffron Colchicum autumnale L., was the first agent discovered in this group as a tubulin depolymerizing agent. The colchicine binding domain is located at the interface between the α and β tubulin dimer.…”
Section: Colchicine Binding Site Agentsmentioning
confidence: 99%
“…Stabilizing agents are able to promote polymeric tubulin structures even when the unfavorable GDP molecule is bound and are more effective than endogenous MT‐associated proteins at stabilizing the MT . There are several drug categories within this class, including taxanes, epothilones, and laulimalide binding site agents . Representative drugs in this class can be found in Figure A.…”
Microtubule (MT)‐targeting agents are highly successful drugs as chemotherapeutic agents, and this is attributed to their ability to target MT dynamics and interfere with critical cellular functions, including, mitosis, cell signaling, intracellular trafficking, and angiogenesis. Because MT dynamics vary in the different stages of the cell cycle, these drugs tend to be the most effective against mitotic cells. While this class of drug has proven to be effective against many cancer types, significant hurdles still exist and include overcoming aspects such as dose limited toxicities and the development of resistance. Newer generations of developed drugs attack these problems and alternative approaches such as the development of dual tubulin and kinase inhibitors are being investigated. This approach offers the potential to show increased efficacy and lower toxicities. This review covers different categories of MT‐targeting agents, recent advances in dual inhibitors, and current challenges for this drug target.
“…The final major category of tubulin inhibitors is colchicine binding site agents. Colchicine (17), from the meadow saffron Colchicum autumnale L., was the first agent discovered in this group as a tubulin depolymerizing agent. The colchicine binding domain is located at the interface between the α and β tubulin dimer.…”
Section: Colchicine Binding Site Agentsmentioning
confidence: 99%
“…Stabilizing agents are able to promote polymeric tubulin structures even when the unfavorable GDP molecule is bound and are more effective than endogenous MT‐associated proteins at stabilizing the MT . There are several drug categories within this class, including taxanes, epothilones, and laulimalide binding site agents . Representative drugs in this class can be found in Figure A.…”
Microtubule (MT)‐targeting agents are highly successful drugs as chemotherapeutic agents, and this is attributed to their ability to target MT dynamics and interfere with critical cellular functions, including, mitosis, cell signaling, intracellular trafficking, and angiogenesis. Because MT dynamics vary in the different stages of the cell cycle, these drugs tend to be the most effective against mitotic cells. While this class of drug has proven to be effective against many cancer types, significant hurdles still exist and include overcoming aspects such as dose limited toxicities and the development of resistance. Newer generations of developed drugs attack these problems and alternative approaches such as the development of dual tubulin and kinase inhibitors are being investigated. This approach offers the potential to show increased efficacy and lower toxicities. This review covers different categories of MT‐targeting agents, recent advances in dual inhibitors, and current challenges for this drug target.
“…Epothilones ( Figure 14 ), which belong also to the microtubule inhibitors, are macrocyclic compounds isolated from the bacterium Sorangium cellulosum based on the 16-membered lactone ring. Six major epothilones, EpoA–EpoF, and more than thirty other related compounds have been identified, so far [ 121 , 122 ]. EpoA ( 13a , Figure 14 ) and EpoB ( 13b , Figure 14 ) are bacterial natural products, while EpoC ( 13e , Figure 14 ) and EpoD ( 13f Figure 14 ), which were discovered later, are their precursors and lack the epoxide group [ 123 ].…”
Section: Microtubule Inhibitorsmentioning
confidence: 99%
“…Their main advantage when compared to compound 9 is enhanced water solubility, which is thirty times higher than that of taxanes, and also efficacy against taxane-resistant tumors [ 124 ]. The epothilone binding site in tubulin significantly overlaps the taxane binding site, therefore, epothilones compete in tubulin binding with compound 9 [ 121 , 125 ].…”
Cancer is one of the greatest challenges of the modern medicine. Although much effort has been made in the development of novel cancer therapeutics, it still remains one of the most common causes of human death in the world, mainly in low and middle-income countries. According to the World Health Organization (WHO), cancer treatment services are not available in more then 70% of low-income countries (90% of high-income countries have them available), and also approximately 70% of cancer deaths are reported in low-income countries. Various approaches on how to combat cancer diseases have since been described, targeting cell division being among them. The so-called mitotic poisons are one of the cornerstones in cancer therapies. The idea that cancer cells usually divide almost uncontrolled and far more rapidly than normal cells have led us to think about such compounds that would take advantage of this difference and target the division of such cells. Many groups of such compounds with different modes of action have been reported so far. In this review article, the main approaches on how to target cancer cell mitosis are described, involving microtubule inhibition, targeting aurora and polo-like kinases and kinesins inhibition. The main representatives of all groups of compounds are discussed and attention has also been paid to the presence and future of the clinical use of these compounds as well as their novel derivatives, reviewing the finished and ongoing clinical trials.
“…We also analyzed the binding pocket of both epothilone and 2l on beta-tubulin and found that there were 12 residues which are common to both 2l and epothilone (Table 5) showing that 2l and epothilone share the same binding pocket. Since the taxol binding pocket has hydrophobic residues in the H7 helix, M loop and β strand of S7, S9-10 ( Ranade et al, 2016), it is possible that 2l also makes some hydrophobic interactions within the binding pocket.…”
Section: Determination Of Binding Site Of 35-bis(styryl)pyrazole 2l mentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.